Clinical trial
Tamoxifen for the Prevention of Breast Cancer in High-Risk Women
NCT00002644 · Queen Mary University of London, Other · Completed
Key facts
| NCT number | NCT00002644 |
|---|---|
| Title | Tamoxifen for the Prevention of Breast Cancer in High-Risk Women |
| Official title | International Breast Cancer Intervention Study: A Multicentre Trial of Tamoxifen to Prevent Breast Cancer |
| Acronym | IBIS-1 |
| Lead sponsor | Queen Mary University of London, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | Tamoxifen Citrate 20Mg Tab, Placebo |
| Enrollment | 7,154 |
| Start date | Jan 1, 1994 |
| Primary completion | Jan 1, 2001 |
| Completion | Mar 30, 2011 |
| First posted | May 11, 2004 |
| Last update posted | Dec 11, 2024 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: